Skip to main content

Animations

MJFF Publications

4351 - 4360 of 8818 Results
Title
Year
  • Year
  • 2018
  • 2015
  • 2021
  • 2013
  • 2019
  • 2009
  • 2019
  • 2015
  • 2017
  • 2017
  • Summary Details
    OPEN
    Title: Monitoring PARKIN RBR Ubiquitin Ligase Activation States with UbFluor
    Journal Name: Current Protocols in Chemical Biology
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1002/cpch.45
    Citation Count: 6
  • Summary Details
    RESTRICTED
    Title: The link between mitochondrial complex I and brain-derived neurotrophic factor in SH-SY5Y cells – The potential of JNX1001 as a therapeutic agent
    Journal Name: European Journal of Pharmacology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.ejphar.2015.07.013
    Citation Count: 20
  • Summary Details
    OPEN
    Title: Low plasma serotonin linked to higher nigral iron in Parkinson’s disease
    Journal Name: Scientific Reports
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1038/s41598-021-03700-2
    Citation Count: 13
  • Summary Details
    OPEN
    Title: Effects of prolonged selective serotonin reuptake inhibition on the development and expression of l-DOPA-induced dyskinesia in hemi-parkinsonian rats
    Journal Name: Neuropharmacology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.neuropharm.2013.09.017
    Citation Count: 63
  • Summary Details
    OPEN
    Title: French validation of the questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease–Rating Scale (QUIP-RS)
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2019.02.026
    Citation Count: 12
  • Summary Details
    RESTRICTED
    Title: Priming for L-DOPA-induced abnormal involuntary movements increases the severity of amphetamine-induced dyskinesia in grafted rats
    Journal Name: Experimental Neurology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.expneurol.2009.04.010
    Citation Count: 46
  • Summary Details
    OPEN
    Title: Method comparison study of the Elecsys® β-Amyloid (1–42) CSF assay versus comparator assays and LC-MS/MS
    Journal Name: Clinical Biochemistry
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.clinbiochem.2019.05.006
    Citation Count: 34
  • Summary Details
    RESTRICTED
    Title: Clinical and imaging markers in premotor LRRK2 G2019S mutation carriers
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2015.08.007
    Citation Count: 37
  • Summary Details
    RESTRICTED
    Title: Improved Neuroimaging Atlas of the Dentate Nucleus
    Journal Name: The Cerebellum
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1007/s12311-017-0872-7
    Citation Count: 26
  • Summary Details
    RESTRICTED
    Title: DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease.
    Journal Name: Neuropharmacology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.neuropharm.2017.11.046
    Citation Count: 20
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.